Latest Ad hoc announcements

Ad hoc announcement pursuant to Art. 53 LR
Ypsomed grows by 21% in the first half of 2025/26 in the core business

Read more...

Ad hoc announcement pursuant to Art. 53 LR
Ypsomed unveils growth roadmap at its Capital Markets Day, as a pure play injection specialist and mission critical part of the pharma value chain

Read more...

All Ad hoc announcements

Ypsomed share YPSN

Share information

Coming events

Zurich

Media and Analyst Conference for the 2025/26 full-year results

We are pleased to announce that Ypsomed will present its 2025/26 full-year results on Wednesday, 20 May 2026.



Browse all events

Financials

We report openly and transparently on our business performance and business model.

Full financial information

Investor agenda

Upcoming and past financial events.

Browse events

Latest news

Browse the ad hoc announcements pursuant to Art. 53 LR.

All ad hoc announcements

Find more ....

Annual General Meeting

Go to the AGM page

Corporate governance & compliance

Read more

News alert

Subscribe to ad hoc announcements.

Subscribe

Shares

Shares, key data, analysts' coverage and more...

Go to shares information

Related information

Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45